1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Uni Bio Science Group, Ltd.

Uni Bio Science Group, Ltd.

HHKEX:690
0.06
HKD
+0.00
(-4.48%)
686.69MMarket Cap
Uni Bio Science Group, Ltd.
HKEX:690
(Hong Kong Exchange)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
0.03
0.06
0.04
0.06
0.03
0.02
0.03
0.03
0.02
0.03
0.03
0.06
0.07
0.08
0.09
0.1
- -
Revenue per Share
-0.08
-0.14
-0.08
-0.05
-0.12
-0.01
-0.01
-0.05
-0.02
- -
-0.01
- -
0.01
0.01
0.01
0.02
- -
Basic EPS, GAAP
-0.02
-0.03
-0.04
-0.04
- -
-0.01
-0.01
-0.02
-0.01
-0.01
- -
- -
- -
0.01
- -
0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.79
0.65
0.59
0.54
0.12
0.1
0.09
0.06
0.03
0.04
0.03
0.03
0.03
0.04
0.05
0.07
0.07
Book Value per Share
0.27
0.21
0.11
0.08
0.07
0.05
0.04
0.04
0.02
0.03
0.03
0.02
0.03
0.03
0.05
0.06
0.06
Tangible Book Value per Share
5,671
1,305
1,305
1,305
3,095
4,998
5,092
5,427
6,176
6,278
6,408
6,372
6,361
6,365
6,140
5,971
5,971
Basic Weighted Avg Shares
148
77
57
83
103
123
146
156
135
209
209
353
440
485
553
586
- -
Sales/Revenue/Turnover
-119.26
-87.25
-144.12
-81.12
-109.84
-40.61
-39.67
-53.13
-89.9
-31.5
-24.62
-1.58
9.6
14.05
16.25
17.07
- -
Operating Margin (%)
89
66
65
62
65
33
29
31
22
21
21
21
18
17
21
22
- -
Depreciation Expense
-455
-185
-103
-69
-366
-60
-56
-279
-139
2
-71
-20
39
71
83
93
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
52.16
- -
- -
11.03
6.62
9.21
8.07
- -
Effective Tax Rate (%)
-306.61
-241.2
-180.38
-83.17
-356.77
-48.47
-38.04
-178.5
-102.45
1.17
-34.16
-5.54
8.75
14.62
14.97
15.92
- -
Profit Margin (%)
69
33
-18
-7
160
112
82
160
65
138
121
109
110
123
195
231
231
Working Capital
- -
2
51
98
- -
- -
- -
- -
- -
- -
2
1
7
38
66
60
60
LT Debt
1,025
848
767
700
598
507
446
343
202
241
189
174
195
257
326
413
413
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
-10.05
- -
- -
17.62
23.52
21.27
18.99
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.23
- -
- -
19.55
26.98
22.23
19.9
- -
Return on Capital (%)
-39.3
-19.78
-12.74
-9.45
-56.43
-10.82
-11.69
-70.75
-50.86
1.11
-33.11
-10.77
20.87
31.37
28.4
25.26
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
49
38
38
LT Borrowings
56
60
56
LT Finance Leases
10
10
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,971
5,971
5,971
Market Capitalization
358
675
687

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
319
342
334
Cash, Cash Equivalents & STI
159
171
169
Accounts Receivable, Net
55
86
68
Inventories
34
18
37
Total Current Liabilities
123
101
104
Payables & Accruals
- -
- -
- -
ST Debt
49
38
38
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.12%
17.87%
26.9%
Free Cash Flow
44.77%
88.42%
27.35%
Net Income, GAAP
-301.36%
-51.11%
12.75%
Sales/Revenue/Turnover
19.06%
24.81%
6.01%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
485
2024
- -
- -
553
2025
- -
- -
586

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
0.01
2025
- -
- -
0.02

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Uni-Bio Science Group Limited (0690.HK) is a Hong Kong-listed investment holding company that researches, develops, manufactures and sells biological and chemical pharmaceutical products to treat human diseases, primarily in the People's Republic of China; it operates through segments including chemical pharmaceutical products, biological pharmaceutical products and pipeline products. The company offers core products such as GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; Boshutai, a small molecule drug to treat diabetes; and Bogutai (teriparatide injection), a disposable injection pen for osteoporosis treatment; it also provides medical aesthetics solutions including medical-grade dressings and cosmeceuticals, alongside pipeline developments like rhPTH 1-34 (UNI-PTH) for postmenopausal osteoporosis, Uni-GLP (a GLP-1 agent) for Type 2 diabetes and obesity, and advanced platforms in regenerative medicine covering muscular-skeletal, skin, ocular, ENT and stem cell technologies with innovations like ECO-KSFA microprotein superfactory and smart hydrogels. Founded in 2001 and headquartered at Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong, the company maintains GMP-certified manufacturing facilities in Beijing and Shenzhen, with main R&D in Guangdong province and a focus on target markets including endocrine disorders, ophthalmology, dermatology, orthopedics and medical aesthetics. Recent developments include the China NMPA approval of Bogutai marketing application, boosting orthopedic treatment options; a May 2024 strategic partnership with Great Bay Bio (GBB) and Tigermed's Pebble Accelerator for innovative weight reduction drugs using AI-driven antibody development; a July 2024 alliance with Chongqing Minji Medical Device Co., Ltd. for exclusive distribution and co-development of fibronectin-based Class II medical aesthetic devices targeting over RMB30 million annual revenue; a September 2025 partnership with Kexing Biopharm to accelerate global expansion of Bogutai; a November 2025 strategic shift toward regenerative medicine leadership with industry-academia collaborations, international partnerships and a new bilingual website launch; and robust 2025 interim financials with profit surging to HK$70.9 million amid e-commerce expansion and preparations for Guangdong centralized drug procurement.